Related Experiment Videos

Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France

Martin Chalumeau1, Sylvie Tonnelier, Philippe D'Athis

  • 1Perinatal and Pediatric Pharmacology Unit, Université René-Descartes, Hôpital Saint-Vincent-de-Paul (AP-HP), Paris, France.

Pediatrics
|June 5, 2003
PubMed

Insights

Fluoroquinolones (FQ) showed higher rates of potential adverse events (PAEs), including musculoskeletal issues, compared to other antibiotics in pediatric patients. This supports limiting FQ use in children to specific situations.

Area of Science:

  • Pediatric pharmacology
  • Infectious disease management

Background:

  • Fluoroquinolones (FQ) are broad-spectrum antibiotics.
  • Concerns exist regarding FQ safety in pediatric populations.

Purpose of the Study:

  • To compare the safety of fluoroquinolones (FQ) versus other antibiotics in children.
  • To evaluate antibiotic-associated potential adverse events (PAEs) in pediatric patients.

Main Methods:

  • A multicenter, observational, comparative cohort study.
  • Matched FQ-exposed and control antibiotic groups (1998-2000).
  • Prospective recording and comparison of PAEs.

Main Results:

  • Higher PAE rates in the FQ group (OR 3.7; 95% CI: 1.9-7.5).
  • Increased musculoskeletal PAEs in FQ group (3.8% vs 0.4%).
  • PAEs led to treatment withdrawal in 11 FQ-exposed patients.

Conclusions:

  • Fluoroquinolone use in pediatric patients is associated with increased potential adverse events.
  • Findings support restricting FQ use to second-line treatment in specific pediatric cases.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...